These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 1573143)

  • 1. An analysis of FDA passive surveillance reports of seizures associated with consumption of aspartame.
    Tollefson L; Barnard RJ
    J Am Diet Assoc; 1992 May; 92(5):598-601. PubMed ID: 1573143
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple chemical sensitivity: controlled scientific studies as proof of causation.
    Tollefson L
    Regul Toxicol Pharmacol; 1993 Aug; 18(1):32-43. PubMed ID: 8234917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Aspartame intolerance.
    Garriga MM; Metcalfe DD
    Ann Allergy; 1988 Dec; 61(6 Pt 2):63-9. PubMed ID: 3061324
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Aspartame: scientific evaluation in the postmarketing period.
    Butchko HH; Stargel WW
    Regul Toxicol Pharmacol; 2001 Dec; 34(3):221-33. PubMed ID: 11754527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Postmarketing surveillance of food additives.
    Butchko HH; Tschanz C; Kotsonis FN
    Regul Toxicol Pharmacol; 1994 Aug; 20(1 Pt 1):105-18. PubMed ID: 7838988
    [TBL] [Abstract][Full Text] [Related]  

  • 6. National adverse drug reaction surveillance. 1986.
    Faich GA; Dreis M; Tomita D
    Arch Intern Med; 1988 Apr; 148(4):785-7. PubMed ID: 3355297
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Botulinum toxin type A injections: adverse events reported to the US Food and Drug Administration in therapeutic and cosmetic cases.
    Coté TR; Mohan AK; Polder JA; Walton MK; Braun MM
    J Am Acad Dermatol; 2005 Sep; 53(3):407-15. PubMed ID: 16112345
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Evaluation of efficacy of heartworm preventive products at the FDA.
    Hampshire VA
    Vet Parasitol; 2005 Oct; 133(2-3):191-5. PubMed ID: 16099105
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Food and Drug Administration monitoring of adverse drug reactions.
    Sills JM; Tanner LA; Milstien JB
    Am J Hosp Pharm; 1986 Nov; 43(11):2764-70. PubMed ID: 3799612
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Food and Drug Administration surveillance of the role of foreign objects in foodborne injuries.
    Hyman FN; Klontz KC; Tollefson L
    Public Health Rep; 1993; 108(1):54-9. PubMed ID: 8434098
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pediatric drug surveillance and the Food and Drug Administration's adverse event reporting system: an overview of reports, 2003-2007.
    Johann-Liang R; Wyeth J; Chen M; Cope JU
    Pharmacoepidemiol Drug Saf; 2009 Jan; 18(1):24-7. PubMed ID: 19009550
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antipsychotics, glycemic disorders, and life-threatening diabetic events: a Bayesian data-mining analysis of the FDA adverse event reporting system (1968-2004).
    DuMouchel W; Fram D; Yang X; Mahmoud RA; Grogg AL; Engelhart L; Ramaswamy K
    Ann Clin Psychiatry; 2008; 20(1):21-31. PubMed ID: 18297583
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Postmarketing reports of QT prolongation and ventricular arrhythmia in association with cisapride and Food and Drug Administration regulatory actions.
    Wysowski DK; Corken A; Gallo-Torres H; Talarico L; Rodriguez EM
    Am J Gastroenterol; 2001 Jun; 96(6):1698-703. PubMed ID: 11419817
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Form for reporting serious adverse events and product problems with human drug and biological products and devices; availability--FDA. Notice.
    Fed Regist; 1993 Jun; 58(105):31596-614. PubMed ID: 10171452
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Postmarketing studies for approved human drug and licensed biological products; status reports. Food and Drug Administration, HHS. Final rule.
    Fed Regist; 2000 Oct; 65(210):64607-19. PubMed ID: 11503687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role of databases in drug postmarketing surveillance.
    Rodriguez EM; Staffa JA; Graham DJ
    Pharmacoepidemiol Drug Saf; 2001; 10(5):407-10. PubMed ID: 11802586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Medical device vigilance at FDA.
    Gross TP; Kessler LG
    Stud Health Technol Inform; 1996; 28():17-24. PubMed ID: 10164091
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Possible neurologic effects of aspartame, a widely used food additive.
    Maher TJ; Wurtman RJ
    Environ Health Perspect; 1987 Nov; 75():53-7. PubMed ID: 3319565
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Monitoring adverse reactions to food additives in the U.S. Food and Drug Administration.
    Tollefson L
    Regul Toxicol Pharmacol; 1988 Dec; 8(4):438-46. PubMed ID: 3222485
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silicone gel breast implant adverse event reports to the Food and Drug Administration, 1984-1995.
    Brown SL; Parmentier CM; Woo EK; Vishnuvajjala RL; Headrick ML
    Public Health Rep; 1998; 113(6):535-43. PubMed ID: 9847926
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.